Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Overview

No overview information available.

Indication

用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染； 2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥； 3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员； 4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少； 5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis	2025/05/25	NCT06989333	Phase 2	Not yet recruiting	Jiuwu Bai
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma	2025/03/25	NCT06799026	Phase 1	Not yet recruiting	David Avigan
Tebentafusp-tebn With LDT in Metastatic UM	2024/10/04	NCT06626516	Phase 1	Not yet recruiting	Thomas Jefferson University
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy	2024/06/25	NCT06472739	Phase 2	Recruiting	Sun Yat-sen University
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial	2024/06/10	NCT06450041	Phase 2	Active, not recruiting	New Approaches to Neuroblastoma Therapy Consortium
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma	2023/08/28	NCT06013618	Phase 2	Recruiting	Sun Yat-sen University
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors	2023/03/30	NCT05790447	Phase 2	Recruiting	Second Affiliated Hospital of Soochow University
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors	2023/03/08	NCT05760196	Phase 2	Recruiting	Xiangpan Li
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)	2022/11/02	NCT05603013	Phase 2	Not yet recruiting	Second Affiliated Hospital of Soochow University
CD30biAb-AATC for CD30+ Malignancies	2022/09/19	NCT05544968	Phase 1	Not yet recruiting	Medical College of Wisconsin

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Savara's Inhaled Molgramostim Shows 9.8% Lung Function Improvement in Phase 3 Autoimmune PAP Trial

6 days ago

Savara's Phase 3 IMPALA-2 trial demonstrated that inhaled molgramostim significantly improved lung function by 9.8% at 24 weeks compared to 3.8% with placebo in autoimmune pulmonary alveolar proteinosis patients.

Greenwich LifeSciences Advances Phase III FLAMINGO-01 Trial for HER2-Positive Breast Cancer Immunotherapy

6 days ago

Greenwich LifeSciences is conducting FLAMINGO-01, a Phase III trial evaluating GLSI-100 immunotherapy to prevent breast cancer recurrences in HER2-positive patients with residual disease.

Transgene and BioInvent to Present Updated BT-001 Oncolytic Virus Data at ESMO 2025

a month ago

Transgene and BioInvent will present updated Phase I data on BT-001, an armed oncolytic virus expressing anti-CTLA-4 antibody, at the ESMO Annual Meeting in Berlin from October 17-21, 2025.

FDA Issues Complete Response Letter for Replimune's RP1 Melanoma Therapy, Citing Trial Design Concerns

a month ago

The FDA issued a Complete Response Letter rejecting Replimune's biologics license application for RP1 plus nivolumab in advanced melanoma, stating the IGNYTE trial does not provide substantial evidence of effectiveness.

Replimune's RP1 Combination Shows Enhanced Response Rates with Deep Tumor Injections in Anti-PD-1 Failed Melanoma

3 months ago

Replimune presented new IGNYTE trial data at ASCO 2025 showing RP1 plus nivolumab achieved a 32.9% objective response rate in anti-PD-1 failed melanoma patients.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access